the international pharmacopoeia - who
TRANSCRIPT
![Page 1: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/1.jpg)
![Page 2: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/2.jpg)
SK | 20 April 20062 |
The International Pharmacopoeia
Dr Sabine Kopp
Quality Assurance and Safety: Medicines
World Health Organization
![Page 3: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/3.jpg)
SK | 20 April 20063 |
The International Pharmacopoeia –Int.Ph.
1. Introduction
2. Int. Ph. - historical overview
3. Int. Ph. - scope
4. WHO consultative procedure
5. Types of monographs
6. Special features
7. Example of a monograph
8. WHO’s strategy in QC
9. WHO’s related activities
![Page 4: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/4.jpg)
SK | 20 April 20064 |
Who is WHO?
192 Member States
Two governing bodies: - World Health Assembly - Executive Board
WHO Secretariat: - headquarters (HQ) - six regional offices (RO)- WHO expert panels(e.g... on The International Pharmacopoeia and Pharmaceutical Preparations)
Constitution 1946, in force since 7 April 1948 (World Health Day)
![Page 5: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/5.jpg)
SK | 20 April 20065 |
The International Pharmacopoeia – myth, mystery or revival
Myth
Oxford Dictionary 7th ed.,1989:
"traditional narrative usu. involving supernatural or fancied persons etc. and embodying popular ideas in natural or social phenomena etc.; such narratives collectively; allegory (Platonic); fictitious person or thing or idea; .. [f.Gk mythos]
![Page 6: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/6.jpg)
SK | 20 April 20066 |
The International Pharmacopoeia – myth, mystery or revival
mystery
Oxford Dictionary 7th ed.1989:
1 "1. hidden or inexplicable matter..2. secrecy, obscurity..; (practice of) making a secret of (unimportant) things. 3. religious truth divinely revealed, esp. one beyond human reasons; religious rite. 4. (in pl).. 5. miracle play. …. .. [ME, f. AF misterie, OF mistere or f.L.f.Gk mysterion,..]
2 "(arch.) handicraft, trade [ME, f. med. L ¨mi(ni)sterium.. ]
![Page 7: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/7.jpg)
SK | 20 April 20067 |
The International Pharmacopoeia– myth, mystery or revival
Revival Oxford Dictionary 7th ed.1989:
"1. bringing or coming back into use or vogue, 2. reawakening of religious fervour, 3. restoration of bodily or mental rigour or to life
or consciousness .."
![Page 8: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/8.jpg)
SK | 20 April 20068 |
The International Pharmacopoeia – myth, mystery or revival
Pharmacopoeia
Oxford Dictionary 7th ed.1989:
"book (esp. one officially published) containing list of drugs with directions for use; stock of drugs [mod. F Gk pharmakopiia (pharmakopoios drug-maker...)]"
![Page 9: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/9.jpg)
SK | 20 April 20069 |
The International Pharmacopoeia – myth, mystery or revival
Pharmacopoeia
The International Pharmacopoeia, preface
"collection of recommended procedures for the analysis and specifications for the determination of pharmaceutical substances, excipients and dosage forms"
Requirements implemented by legislation
![Page 10: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/10.jpg)
SK | 20 April 200610 |
International PharmacopoeiaHistorical overview
→ 1874 Discussion on Unification of terminology andcomposition of drugs
→ 1902 First Conference organized by theGovernment of Belgium
→ 1906 Agreement on Unification of the Formulae ofPotent Drugs ratified by 19 states
→ 1925 Brussels agreement (signed 1929)→ League of Nations:
“international pharmacopoeia”
![Page 11: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/11.jpg)
SK | 20 April 200611 |
International PharmacopoeiaHistorical overview - 2 -
→ 1937 First meeting (experts from B, CH, DK, F, NL, UK, USA) - League of Nations
→ 1947 Interim Commission of WHO takes up healthrelated work of League of Nations
→ 1948 First World Health Assembly establishedExpert Committee on Unification of Pharmacopoeia
![Page 12: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/12.jpg)
SK | 20 April 200612 |
International PharmacopoeiaHistorical overview - 3 -
→ 1950 WHA approved publication of PharmacopoeiaInternationalis
WHO Expert Committee:→ 1951 named: Expert Committee on International
Pharmacopoeia → 1959 named: Expert Committee on Specifications
for Pharmaceutical Preparations --> to date
![Page 13: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/13.jpg)
SK | 20 April 200613 |
International Pharmacopoeia
→ current: Third edition, 4th edition in press!→ implementation: “ready for use” by Member
States→ Scope since 1975:
→Model List of Essential Medicines and →Drugs recommended by WHO Specific
disease programmes, e.g. Malaria, TB, HIV/AIDS
![Page 14: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/14.jpg)
SK | 20 April 200614 |
WHO Procedure for the preparation of drug Quality Control specifications (1)
…..or why it takes so long….
Preliminary consultation and drafting Draft Quality Control specifications Method development + validation: WHO Collaborating Centres and experts, contracted laboratories Circulation for comments + testing of samplesRevision process, additional studies, contacts with manufacturers for queries and additional samples as needed..........
![Page 15: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/15.jpg)
SK | 20 April 200615 |
WHO does the work … with Partners
National and regional authorities
International organizations (UNAIDS, UNFPA, UNICEF, World Bank, WIPO, WTO, WCO, etc.)
International professional and other associations, NGOs (including consumer associations, MSF, industry: IFPMA-IGPA-WSMI, FIP, WMA, etc.)
WHO Expert Panels (official nomination process)
Specialists from all areas, regulatory, university, industry………
WHO Collaborating Centres (official nomination process)
Pharmacopoeia Commissions and Secretariats, national institutions and institutes ..
Regional and interregional groups (ICH…)
![Page 16: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/16.jpg)
SK | 20 April 200616 |
WHO Procedure for the preparation of drug Quality Control specifications (2)
..........
Adoption by WHO Expert Committee on Specifications for Pharmaceutical Preparations
Presentation to WHO Governing Bodies
Recommendation to governments for implementation
→publication in Technical Reports and
→The International Pharmacopoeia and Basic Tests series
![Page 17: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/17.jpg)
SK | 20 April 200617 |
What is a WHO Expert Committee?
Official advisory body to Director-General of WHO
Governed though rules and procedures (Ref. WHO Manual)
Participation in Expert Committee (EC) meetings:– Voting members ("Expert") selected from WHO Panel of Experts– Technical advisers– Observers: - international organizations, - NGOs, etc.
Report of EC (including adopted guidelines) presented to WHO Governing Bodies for final comments, endorsement and implementation by Member States
WHO technical guidance
![Page 18: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/18.jpg)
SK | 20 April 200618 |
How to become a "WHO Expert"?
Official nomination process
Upon proposal to WHO in consultation with:• Member State/national government (citizenship)+• WHO Regional Office (in accordance with Member State) +• WHO headquarters
Period of maximum 4 years
Possibility to renew
![Page 19: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/19.jpg)
SK | 20 April 200619 |
Type of monographs
→ Drug substances→ Excipients→ Finished dosage forms→ General methods and requirements:
→ oral sold dosage forms, e.g. tablets→ dissolution testing…
![Page 20: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/20.jpg)
SK | 20 April 200620 |
Some Figures
→ Volume 1:42 General methods and requirements
→ Volume 2:88 Active pharmaceutical ingredients
→ Volume 3:100 Active pharmaceutical ingredients
![Page 21: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/21.jpg)
SK | 20 April 200621 |
Some Figures
→ Volume 4:23 Active pharmaceutical ingredients65 Excipients25 Oral dosage forms14 Injectables11 General methods and requirements
![Page 22: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/22.jpg)
SK | 20 April 200622 |
Some Figures
→ Volume 5:20 Oral dosage forms39 Active pharmaceutical ingredients9 General methods and requirements
Special section on antimalarial agents, artemisinin derivatives:antimalarial agents, artemisinin derivatives:5 Active pharmaceutical ingredients 8 Oral dosage forms
+ General guidance texts on INNs, graphic formulae, establishment of RS...
![Page 23: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/23.jpg)
SK | 20 April 200623 |
Specifications adopted by WHO Expert Committee – status March 2006
Monographs for Antiretrovirals (API):
abacavir sulfate
didanosine
efavirenz
indinavir sulfate
nelfinavir
nevirapine
lamivudine
ritonavir
saquinavir
saquinavir sulfate
stavudine
zidovudine
![Page 24: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/24.jpg)
SK | 20 April 200624 |
Specifications adopted by 40th WHO Expert Committee (status March 2006)
Antiretrovirals (finished dosage forms):
nelfinavir mesilate tablets
nelfinavir mesilate oral powder
saquinavir mesilate capsules
.. More to come...
![Page 25: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/25.jpg)
SK | 20 April 200625 |
Specifications adopted by 40th WHO Expert Committee (status March 2006)
Fixed-dose antituberculosis medicines: rifampicin tablets
rifampicin capsules
rifampicin + isoniazid tablets
rifampicin + isoniazid + pyrazinamide + ethambutol HCl tablets
isoniazid + ethambutol HCl tablets
rifampicin + isoniazid + pyrazinamide tablets
![Page 26: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/26.jpg)
SK | 20 April 200626 |
International PharmacopoeiaSpecial features:
1. ….when complex, technically demanding methods are described (e.g. HPLC),
--> a less technically demanding analytical method(e.g. TLC) proposed as alternative (if possible).
2. …. international validation - impurity profile can vary from country to country!!
![Page 27: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/27.jpg)
SK | 20 April 200627 |
Example of monograph - didanosineExample of monograph - didanosine
DIDANOSINEC10H12N4O3
Relative Molecular Mass. 236.2
Chemical name. 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-(2,3-dideoxy-β-D-glycero-pentofuranosyl)-1,9-dihydro-6H-purin-6-one; 2',3'-dideoxyinosine (DDI); CAS Reg. No. 69655-05-6.
Description. A white to almost white powder.
Solubility. Sparingly soluble in water; slightly soluble in methanol R and ethanol (95 per cent) R
Category. Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor).
Storage. Didanosine should be kept in a tightly closed container.
![Page 28: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/28.jpg)
SK | 20 April 200628 |
Didanosine monograph: RequirementsDidanosine monograph: Requirements
Identity testSpecific Optical RotationHeavy metalsSulfated ashLoss on dryingRelated SubstancesAssayImpurities Reagents
![Page 29: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/29.jpg)
SK | 20 April 200629 |
Didanosine - AssayDidanosine - Assay
Dissolve about 0.200 g, accurately weighed, in 50 ml glacial acetic acid R1 and titrate with perchloric acid (0.1 mol/l) VS as described under “Non-aqueous titration”; Method A (Vol. 1, p.131) determining the end-point potentiometrically.
Each ml of perchloric acid (0.1 mol/l) VS is equivalent to 23.62 mg of C10H12N4O3.
![Page 30: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/30.jpg)
SK | 20 April 200630 |
Related Substances (extract)Related Substances (extract)
Note: Prepare fresh solutions and perform the tests without delay
Carry out the test as described under “High-performance liquid chromatography” (Vol. 5, p. 257), using a stainless steel column (25cm x 4.6mm), packed with octadecylsilyl base-deactivated silica gel for chromatography R (5µm)[1].
Maintain the column temperature at 20 – 25°C.
The mobile phases for gradient elution consist of a mixture of aqueous phase (Mobile phase A) and methanol (Mobile phase B), using the following conditions :
Mobile phase A: A 0.05 M solution of ammonium acetate R adjusted to pH 8.0 using a 20% v/v ammonia (∼260 g/l) TS .
Mobile phase B: Methanol.………………….1 Hypersil BDS is suitable.
![Page 31: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/31.jpg)
SK | 20 April 200631 |
Didanosine- ImpuritiesDidanosine- Impurities
The following list of known and potential impurities that have been shown to be controlled by the tests in this monograph is given for information.
A. 1,7-dihydro-6H-purin-6-one (hypoxanthine)
B. 9-β-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one (inosine)
C. 9-(2-deoxy- β-D-erythro-pentofuranosyl)-1,9-dihydro-6H-purin-6-one (2'-deoxyinosine)
D. 9-(3-deoxy-β-D-erythro-pentofuranosyl)-1,9-dihydro-6H-purin-6-one (3'-deoxyinosine)
E. 9-(2,3-anhydro-β-D-ribofuranosyl)-1,9-dihydro-6H-purin-6-one (2',3'-anhydroinosine)
…..
![Page 32: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/32.jpg)
SK | 20 April 200632 |
WHO’s strategy for quality control
→ Step-wise approach:
Basic tests (identification)Screening tests (TLC)The International PharmacopoeiaInternational reference materials
(ICRS and IR reference spectra)
![Page 33: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/33.jpg)
SK | 20 April 200633 |
Int. Ph. and links with other programmes and organizations
→ Establishment of monographs for antiretrovirals
collaboration Ph.Eur. USP, JP, IP, Chinese Pharmacopoeia, Brazilian Pharmacopoeia ...collaboration with manufacturers links with WHO-UNICEF project on prequalification of suppliers for HIV drugs
![Page 34: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/34.jpg)
SK | 20 April 200634 |
Int. Ph. and links with other programmes and organizations
→ Monographs for antimalarials, anti-TB drugs (different clusters in WHO)
→ General requirements for products derived from plant materials (WHO Traditional Medicines Programme)
→ Monographs for radiopharmaceuticals (with International Atomic Energy Agency - IAEA)
→ Monographs for excipients (with Pharmacopoeial Discussion Group - PDG)
![Page 35: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/35.jpg)
SK | 20 April 200635 |
WHO’s related activities (1)
→ International Chemical Reference Substances (ICRS)→ International IR reference spectra → Good Practices for National Pharmaceutical Control
Laboratories → Model Certificate of Analysis → Considerations for requesting analysis of drug samples→ Basic and screening tests
![Page 36: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/36.jpg)
SK | 20 April 200636 |
WHO’s related activities (2)
WHO good manufacturing practice (GMP) for pharmaceutical products and starting materials (active ingredients and excipients)
Good Trade and Distribution Practices for Pharmaceutical Starting Materials and Good distribution practices for medicines
WHO Good Storage Practices (GSP)
WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce and WHO Pharmaceutical Starting Materials Certification Scheme (SMACS)
..............
![Page 37: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/37.jpg)
SK | 20 April 200637 |
INNsINNs
![Page 38: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/38.jpg)
SK | 20 April 200638 |
What needs to be kept in mind!!What needs to be kept in mind!!
1. Quality cannot be tested into theproduct!
![Page 39: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/39.jpg)
SK | 20 April 200639 |
What needs to be kept in mind!!What needs to be kept in mind!!
2. Specifications in national and regional pharmacopoeias are:
- based on manufacturers' specifications
- specific for the product(s) marketed in its legislative territory
![Page 40: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/40.jpg)
SK | 20 April 200640 |
What needs to be kept in mind!!What needs to be kept in mind!!
3. Specifications should be used in a comprehensive way, i.e. including all tests listed
4. Specifications should be used intelligently, there is no guarantee that all (possible and impossible) impurities and alterations are covered!
![Page 41: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/41.jpg)
SK | 20 April 200641 |
The International Pharmacopoeia's advantages (1)
The International Pharmacopoeia's advantages (1)
1. Specifications validated internationally, through an independent scientific process2. Input from WHO Collaborating Centres, national Drug Quality Control laboratories 3. Collaboration with manufacturers around the world, especially for new projects
![Page 42: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/42.jpg)
SK | 20 April 200642 |
The International Pharmacopoeia's advantages (2)
The International Pharmacopoeia's advantages (2)
4. Collaboration with standard-setting organizations and parties, including regional and national pharmacopoeias 5. Networking and close collaboration with WHO Member States, Drug Regulatory Authorities 6. Links with other WHO activities 7. FREE FOR USE by all Member States
![Page 43: The International Pharmacopoeia - WHO](https://reader030.vdocuments.mx/reader030/viewer/2022012503/617d8cda3525146f483473f7/html5/thumbnails/43.jpg)
SK | 20 April 200643 |
Further questions ??????http:www.who.int/medicines